ES2142353T3 - Procedimiento para reducir los niveles de colesterol total y de colesterol asociado a lipoproteinas de baja densidad en sangre. - Google Patents

Procedimiento para reducir los niveles de colesterol total y de colesterol asociado a lipoproteinas de baja densidad en sangre.

Info

Publication number
ES2142353T3
ES2142353T3 ES93921585T ES93921585T ES2142353T3 ES 2142353 T3 ES2142353 T3 ES 2142353T3 ES 93921585 T ES93921585 T ES 93921585T ES 93921585 T ES93921585 T ES 93921585T ES 2142353 T3 ES2142353 T3 ES 2142353T3
Authority
ES
Spain
Prior art keywords
blood
cholesterol
reduce
low
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93921585T
Other languages
English (en)
Inventor
Steven L Nissen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation UIRF
Iowa State University Research Foundation ISURF
Original Assignee
University of Iowa Research Foundation UIRF
Iowa State University Research Foundation ISURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25484425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2142353(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Iowa Research Foundation UIRF, Iowa State University Research Foundation ISURF filed Critical University of Iowa Research Foundation UIRF
Application granted granted Critical
Publication of ES2142353T3 publication Critical patent/ES2142353T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

PACIENTES CON NIVELES ELEVADOS EN SANGRE DE LIPOPROTEINA DE BAJA DENSIDAD (LDL) Y COLESTEROL TOTAL SON TRATADOS ADMINISTRANDO ACIDO (BETA)-HIDROXI-(BETA)-METILBUTIRICO (HMB) PARA REDUCIR EL NIVEL EN SANGRE DEL PACIENTE DE LDL Y COLESTEROL TOTAL. EL HMB PUEDE SER SEGURAMENTE ADMINISTRADO ORALMENTE A HUMANOS EN CANTIDADES QUE INCLUSO REDUCEN SIGNIFICATIVAMENTE NIVELES EN SANGRE DE COLESTEROL TOTAL Y LDL.
ES93921585T 1992-09-16 1993-09-15 Procedimiento para reducir los niveles de colesterol total y de colesterol asociado a lipoproteinas de baja densidad en sangre. Expired - Lifetime ES2142353T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94640492A 1992-09-16 1992-09-16

Publications (1)

Publication Number Publication Date
ES2142353T3 true ES2142353T3 (es) 2000-04-16

Family

ID=25484425

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93921585T Expired - Lifetime ES2142353T3 (es) 1992-09-16 1993-09-15 Procedimiento para reducir los niveles de colesterol total y de colesterol asociado a lipoproteinas de baja densidad en sangre.

Country Status (12)

Country Link
US (1) US5360613A (es)
EP (1) EP0660706B1 (es)
JP (1) JP3148243B2 (es)
AU (1) AU673002B2 (es)
BR (1) BR9307035A (es)
CA (1) CA2142314C (es)
DE (1) DE69327468T2 (es)
ES (1) ES2142353T3 (es)
FI (1) FI951218A (es)
NO (1) NO951000D0 (es)
NZ (1) NZ256300A (es)
WO (1) WO1994006417A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US6103764A (en) * 1997-11-07 2000-08-15 Iowa State University Research Foundation, Inc. Method for increasing the aerobic capacity of muscle
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
AU2620600A (en) * 1999-01-21 2000-08-07 Steroidogenesis Inhibitors International Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
EP1399138B1 (de) 2001-05-18 2006-02-08 Lonza Ag Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat
US20040048925A1 (en) * 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US6812249B2 (en) * 2003-03-04 2004-11-02 Sal Abraham Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
EP1750527A1 (en) * 2004-03-11 2007-02-14 Wiley Organics, Inc. Compositions and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
WO2007056176A2 (en) * 2005-11-03 2007-05-18 Southwest Immunology, Inc. Compositions for preventing and reducing delayed onset muscle soreness
RU2469719C2 (ru) 2005-12-19 2012-12-20 Абботт Лаборэтриз СПОСОБ ЛЕЧЕНИЯ АЛЛЕРГИИ, СПОСОБ ЛЕЧЕНИЯ АСТМЫ, СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИИ И СПОСОБ ЛЕЧЕНИЯ СОСТОЯНИЯ, ХАРАКТЕРИЗУЮЩЕГОСЯ ДИСБАЛАНСОМ СОДЕРЖАНИЯ ЦИТОКИНОВ ТИПОВ 1 И 2, ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА
US20080200422A1 (en) * 2007-01-09 2008-08-21 Cavener Douglas R Methods for reduction of adipose tissue mass
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9539224B2 (en) 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9770424B2 (en) 2008-12-09 2017-09-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
HUE039841T2 (hu) 2008-12-09 2019-02-28 Metabolic Tech Inc Táplálkozási beavatkozás izomfunkció és erõ növeléséhez
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11042605B2 (en) 2009-07-21 2021-06-22 Ccqcc Corp. Method and apparatus for calibration and testing of scientific measurement equipment
US8538727B2 (en) * 2009-07-21 2013-09-17 George S. Cembrowski Method and apparatus for calibration and testing of scientific measurement equipment
CA2785523A1 (en) 2010-01-29 2011-08-04 Abbott Laboratories Aseptically packaged nutritional liquids comprising hmb
EP2528459B1 (en) 2010-01-29 2014-06-11 Abbott Laboratories Nutritional emulsions comprising calcium hmb
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
CA2841748C (en) * 2011-07-15 2021-06-15 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
CN103857390A (zh) * 2011-08-15 2014-06-11 雅培制药有限公司 用于制备hmb及其盐的方法
WO2013067485A1 (en) 2011-11-03 2013-05-10 University Of Florida Research Foundation, Inc. Nutritional supplement for weight management
WO2012140276A2 (en) * 2011-11-17 2012-10-18 Lonza Ltd Process for the preparation of 3-hydroxy-3-methylbutyric acid or its calcium salts
CA2884405C (en) 2012-09-10 2021-03-30 Metabolic Technologies, Inc. Composition of hmb and atp and methods of use
EP3122348B1 (en) 2014-03-27 2020-05-27 Winterfield, Roland, W. Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
AU2016323779B2 (en) 2015-09-16 2022-03-17 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
EP3385250B1 (en) * 2015-11-19 2021-10-20 Kyowa Hakko Bio Co., Ltd. Crystals of monovalent cation salt of 3-hydroxyisovaleric acid, and method for producing said crystals
EP3405262A4 (en) 2016-01-21 2019-08-28 Metabolic Technologies, Inc. COMPOSITIONS AND METHODS OF USING BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) FOR MODULATING AUTOPHAGIA AND LIPOPHAGIA
SG11201811493UA (en) 2016-06-24 2019-01-30 Otsuka Pharma Factory Inc Crystal of amino acid salt of 3-hydroxyisovaleric acid and production method thereof
EP3528801A4 (en) 2016-10-21 2020-07-15 Metabolic Technologies, Inc. COMPOSITIONS AND METHODS OF USE OF BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) AND PROBIOTICS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629449A (en) * 1968-04-22 1971-12-21 Majid Siddiqi Process of combatting hypercholesterolemia
US4764531A (en) * 1986-03-11 1988-08-16 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to laying chickens
US4760090A (en) * 1986-03-11 1988-07-26 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to cattle and sheep
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals

Also Published As

Publication number Publication date
NO951000L (no) 1995-03-15
DE69327468T2 (de) 2000-05-11
AU4922593A (en) 1994-04-12
CA2142314A1 (en) 1994-03-31
JPH08501777A (ja) 1996-02-27
FI951218A0 (fi) 1995-03-15
JP3148243B2 (ja) 2001-03-19
EP0660706A4 (es) 1995-07-26
EP0660706A1 (en) 1995-07-05
NO951000D0 (no) 1995-03-15
EP0660706B1 (en) 1999-12-29
DE69327468D1 (de) 2000-02-03
NZ256300A (en) 1997-06-24
AU673002B2 (en) 1996-10-24
CA2142314C (en) 1999-06-01
US5360613A (en) 1994-11-01
BR9307035A (pt) 1999-06-29
FI951218A (fi) 1995-03-15
WO1994006417A1 (en) 1994-03-31

Similar Documents

Publication Publication Date Title
ES2142353T3 (es) Procedimiento para reducir los niveles de colesterol total y de colesterol asociado a lipoproteinas de baja densidad en sangre.
Lebwohl et al. Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy
ES2080042T3 (es) Composiciones para modular el efecto de tnf e il-1.
BR9106977A (pt) Metodo para suprimir destruicao autoimune de celuias beta pancreaticas,formulacao farmaceutica,metodo de profilaxia,metodo para prevenir o surgimento de diabetes tipo 1 e metodo para tratar um mamifero
ES2164097T3 (es) Uso de anestesicos topicos para la fabricacion de un medicamento para el tratamiento del asma bronquial.
ES2036593T3 (es) Composiciones que utilizan medicamentos antiinflamatorios no esteroidales encapsulados en liposomas.
DK0542864T3 (da) Anvendelse af phospholipider til fremstilling af et topisk lægemiddel til modifikation af serumcholesterolniveauer
AR042262A2 (es) Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
ES2074565T3 (es) Empleo de melatonina para tratar el sindrome pre-menstrual.
ES2176197T3 (es) Sistema de administracion transdermal que contiene un acido acetilsalicilico para la terapia de trombosis y la profilaxis del cancer.
SE8803248L (sv) Anvaendning av inositoltrifosfat foer framstaellning av laekemedel
KR950702120A (ko) 골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis)
ES2063767T3 (es) Esteres aromaticos policiclicos de antibioticos macrolidicos y lincosamidicos, su procedimiento de preparacion y composiciones farmaceuticas y cosmeticas que los contienen.
DK258884D0 (da) Peptider og farmaceutisk praeparat indeholdende et saadant peptid
KR910005858A (ko) 지방산 요법
SE7711102L (sv) Nya medel och nya sett att behandla klimakteriska bortfallsymptom
DK0714304T3 (da) Terapeutisk system til behandling af psoriasis
DK0484112T3 (da) Anvendelse af lithium ved behandlingen eller profylakse af Molluscum contagiosum
Beasley et al. Thyroid gland influences the period of hamster circadian oscillations
RU93048868A (ru) Способ безопасного введения жирных кислот, его применение для лечения рака, инфекционных вирусных заболеваний и других нарушений
ES541944A0 (es) Procedimiento para preparar liposomas que contiene alergenoso fracciones de alergenos inhalables
ES2087764T3 (es) Uso del ajo de oso en el tratamiento o prevencion de los trastornos circulatorios.
ATE130194T1 (de) Subkutane verabreichung des humanen choriongonadotropins.
ES2053925T3 (es) Una composicion para el tratamiento de pacientes con sindrome de inmunodeficiencia adquirida.
DE3064854D1 (en) Quail-egg lyophilisate for the treatment of immuno-allergic diseases

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 660706

Country of ref document: ES